Burkholderia pseudomallei is the cause of a severe and potentially fatal infectious disease called melioidosis. This bacteria, generally found in tropical and subtropical regions, is labelled as a Tier 1 select agent by the CDC. In order to discover effective treatments for melioidosis, inhibitors of Burkholderia pseudomallei IspF are being investigated. The MEP pathway is used by most bacteria to produce IPP and DMAPP. Inhibition of the MEP pathway is desirable since it is not found in humans which may limit side effects. This research focuses on developing inhibitors of the enzyme from the fifth step of the MEP pathway, IspF. Starting with the lead compound, L-tryptophanhydroxamic acid, analogues were designed, synthesized, and assayed for antibacterial activity and binding affinity. This poser will describe the observed Structure Activity Relationships.

Derivatives of L-tryptophanhydroxamic acid as potential inhibitors of Burkholderia pseudomallei IspF

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.